SHANDONG XINHUA (00719) Receives Approval Notice for Prednisolone Acetate API Marketing Application

Stock News11-27

SHANDONG XINHUA (00719) announced that it recently received the "Chemical Drug API Marketing Approval Notice" for Prednisolone Acetate from the National Medical Products Administration (NMPA).

In March 2024, the company submitted the registration application for the domestic production of Prednisolone Acetate as a chemical active pharmaceutical ingredient (API) to the NMPA's Center for Drug Evaluation (CDE), which was subsequently accepted. The approval notice was granted in November 2025, with the review conclusion confirming the registration.

Prednisolone Acetate is primarily used for allergic and autoimmune inflammatory diseases, including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, granulocytopenia, adrenal cortex insufficiency, severe dermatitis, and acute leukemia. It is also applied in the comprehensive treatment of certain infections.

According to relevant statistics, sales of Prednisolone Acetate-related formulations in China's public medical institutions reached approximately RMB 100 million in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169274526?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169274526","market":"us","top_or_hot":-1,"title":"SHANDONG XINHUA (00719) Receives Approval Notice for Prednisolone Acetate API Marketing Application","media":"Stock News","content":"<p>SHANDONG XINHUA (00719) announced that it recently received the \"Chemical Drug API Marketing Approval Notice\" for Prednisolone Acetate from the National Medical Products Administration (NMPA).</p>\n<p>In March 2024, the company submitted the registration application for the domestic production of Prednisolone Acetate as a chemical active pharmaceutical ingredient (API) to the NMPA's Center for Drug Evaluation (CDE), which was subsequently accepted. The approval notice was granted in November 2025, with the review conclusion confirming the registration.</p>\n<p>Prednisolone Acetate is primarily used for allergic and autoimmune inflammatory diseases, including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, granulocytopenia, adrenal cortex insufficiency, severe dermatitis, and acute leukemia. It is also applied in the comprehensive treatment of certain infections.</p>\n<p>According to relevant statistics, sales of Prednisolone Acetate-related formulations in China's public medical institutions reached approximately RMB 100 million in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHANDONG XINHUA (00719) Receives Approval Notice for Prednisolone Acetate API Marketing Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHANDONG XINHUA (00719) Receives Approval Notice for Prednisolone Acetate API Marketing Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANDONG XINHUA (00719) announced that it recently received the \"Chemical Drug API Marketing Approval Notice\" for Prednisolone Acetate from the National Medical Products Administration (NMPA).</p>\n<p>In March 2024, the company submitted the registration application for the domestic production of Prednisolone Acetate as a chemical active pharmaceutical ingredient (API) to the NMPA's Center for Drug Evaluation (CDE), which was subsequently accepted. The approval notice was granted in November 2025, with the review conclusion confirming the registration.</p>\n<p>Prednisolone Acetate is primarily used for allergic and autoimmune inflammatory diseases, including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, granulocytopenia, adrenal cortex insufficiency, severe dermatitis, and acute leukemia. It is also applied in the comprehensive treatment of certain infections.</p>\n<p>According to relevant statistics, sales of Prednisolone Acetate-related formulations in China's public medical institutions reached approximately RMB 100 million in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00719","symbol_name":"山东新华制药股份","start_time":0,"source_url":"","article_id":"1169274526","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169274526","pubTimestamp":1764232955,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SHANDONG XINHUA (00719) announced that it recently received the \"Chemical Drug API Marketing Approval Notice\" for Prednisolone Acetate from the National Medical Products Administration (NMPA). In...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00719":"山东新华制药股份","BK1515":"抗疫概念","BK1191":"制药"},"translate_title":"山东新华(00719)收到醋酸泼尼松龙原料药上市申请批准通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"SHANDONG XINHUA (00719) announced that it recently received the \"Chemical Drug API Marketing Approval Notice\" for Prednisolone Acetate from the National Medical Products Administration (NMPA).\nIn March 2024, the company submitted the registration application for the domestic production of Prednisolone Acetate as a chemical active pharmaceutical ingredient (API) to the NMPA's Center for Drug Evaluation (CDE), which was subsequently accepted. The approval notice was granted in November 2025, with the review conclusion confirming the registration.\nPrednisolone Acetate is primarily used for allergic and autoimmune inflammatory diseases, including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, granulocytopenia, adrenal cortex insufficiency, severe dermatitis, and acute leukemia. It is also applied in the comprehensive treatment of certain infections.\nAccording to relevant statistics, sales of Prednisolone Acetate-related formulations in China's public medical institutions reached approximately RMB 100 million in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169274526","isCrawlerRequest":true}